Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Major Shareholder Sells $762,266.84 in Stock

NewAmsterdam Pharma (NASDAQ:NAMS) major shareholder Nap B.V. Forgrowth sold 29,846 shares of NewAmsterdam Pharma stock in a transaction on Monday, December 30th. The stock was sold at an average price of $25.54, for a total transaction of $762,266.84. Following the sale, the insider now owns 10,656,172 shares in the company, valued at $272,158,632.88. This represents a 0.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Nap B.V. Forgrowth also recently made the following trade(s):

• On Thursday, December 26th, Nap B.V. Forgrowth sold 33,438 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $26.01, for a total value of $869,722.38.
• On Monday, December 23rd, Nap B.V. Forgrowth sold 25,132 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.49, for a total value of $640,614.68.
• On Friday, December 20th, Nap B.V. Forgrowth sold 49,772 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $25.60, for a total value of $1,274,163.20.
• On Wednesday, December 18th, Nap B.V. Forgrowth sold 100,728 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $26.10, for a total value of $2,629,000.80.
• On Thursday, December 12th, Nap B.V. Forgrowth sold 166,011 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.39, for a total transaction of $4,215,019.29.
• On Monday, November 18th, Nap B.V. Forgrowth sold 33,273 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $25.08, for a total transaction of $834,486.84.
• On Friday, November 15th, Nap B.V. Forgrowth sold 8,530 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.02, for a total transaction of $213,420.60.

NewAmsterdam Pharma Stock Down 0.1 %

Shares of NewAmsterdam Pharma stock opened at $25.94 on Friday. The company has a 50-day moving average of $22.67 and a two-hundred day moving average of $19.42. NewAmsterdam Pharma has a 12-month low of $11.57 and a 12-month high of $27.29.

Analyst Ratings Changes

A number of analysts have weighed in on NAMS shares. Needham & Company LLC reaffirmed a “buy” rating and set a $36.00 price objective on shares of NewAmsterdam Pharma in a research report on Thursday, December 5th. Scotiabank boosted their price target on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a “sector outperform” rating in a research note on Wednesday, December 11th. Piper Sandler restated an “overweight” rating and issued a $37.00 price objective on shares of NewAmsterdam Pharma in a research report on Monday, September 23rd. Finally, HC Wainwright started coverage on NewAmsterdam Pharma in a research note on Monday, December 30th. They set a “buy” rating and a $48.00 target price for the company. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $38.17.

Hedge Funds Weigh In On NewAmsterdam Pharma

Several hedge funds have recently bought and sold shares of NAMS. Geode Capital Management LLC grew its holdings in NewAmsterdam Pharma by 1.6% in the third quarter. Geode Capital Management LLC now owns 86,322 shares of the company’s stock valued at $1,433,000 after purchasing an additional 1,399 shares during the last quarter. Banque Cantonale Vaudoise acquired a new stake in NewAmsterdam Pharma in the 2nd quarter valued at about $38,000. Quarry LP increased its holdings in NewAmsterdam Pharma by 2,469.2% during the 3rd quarter. Quarry LP now owns 6,500 shares of the company’s stock valued at $108,000 after acquiring an additional 6,247 shares in the last quarter. Barclays PLC raised its position in NewAmsterdam Pharma by 1,813.4% during the third quarter. Barclays PLC now owns 7,596 shares of the company’s stock worth $126,000 after acquiring an additional 7,199 shares during the last quarter. Finally, Bellevue Group AG purchased a new stake in shares of NewAmsterdam Pharma in the third quarter valued at about $128,000. 89.89% of the stock is owned by hedge funds and other institutional investors.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.